Samsung Bioepis links with Sandoz to commercialize ustekinumab biosimilar candidate

11 September 2023

Samsung Bioepis has entered into a commercialization agreement with Sandoz for SB17, a proposed biosimilar to Johnson & Johnson (NYSE: JNJ) subsidiary Janssen’s Stelara (ustekinumab).

The South Korean biosimilars company says this marks a step forward in strengthening access to Samsung Bioepis’ immunology portfolio in the USA, Canada, European Economic Area (EEA), Switzerland and the UK. Stelara is one of J&J’s top-selling drugs, bringing in revenues of $2.98 billon in the second quarter of 2023.

“This agreement is a testament to Samsung Bioepis’ strong track record in the field of immunology, demonstrating a potential value that our biosimilars could deliver for widening access to biologic medicines.” said Sang-Jin Pak, executive vice president and head of Commercial Division, at Samsung Bioepis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK